Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
|
| gptkbp:alternativeName |
gptkb:Dianabol
|
| gptkbp:brand |
gptkb:methandrostenolone
|
| gptkbp:class |
gptkb:anabolic_steroid
|
| gptkbp:compatibleWith |
gptkb:FDA
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Canada
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:developedBy |
1950s
|
| gptkbp:marketedIn |
various countries
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
water retention
acne liver toxicity gynecomastia |
| gptkbp:usedBy |
bodybuilders
|
| gptkbp:usedFor |
muscle growth
|
| gptkbp:bfsParent |
gptkb:methandrostenolone
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anabol
|